Association between insulin-like growth factor-1 polymorphisms and stomach cancer risk in a Japanese population

Cancer Science

Volumn 102, Issue 12, 2011, Pages 2231-2235

  Ennishi, Daisuke ^a,b   Shitara, Kohei ^a   Ito, Hidemi ^a   Hosono, Satoyo ^a   Watanabe, Miki ^a   Ito, Seiji ^a   Sawaki, Akira ^a   Yatabe, Yasushi ^a   Yamao, Kenji ^a   Tajima, Kazuo ^a   Tanimoto, Mitsune ^b   Tanaka, Hideo ^a,c   Hamajima, Nobuyuki ^c   Matsuo, Keitaro ^a,c  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN C;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HUMAN; IGF1 GENE; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 81855182163     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02062.x     Document Type: Article

References (24)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64.
2. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev 2008; 8: 915-28.
3. Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway - therapeutic perspectives in cancer. Nat Clin Prac Oncol 2007; 4: 591-602.
4. Karamouzis MV, Papavassiliou AG. The IGF-1 network in lung carcinoma therapeutics. Trends Mol Med 2006; 12: 595-602.
5. Chan JM, Stampfer MJ, Ma J et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099-106.
6. Cheng I, Stram DO, Penney KL et al. Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst 2006; 98: 123-34.
7. Wolk A, Mantzoros CS, Andersson SO et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-5.
8. Setiawan VW, Cheng I, Stram DO et al. Igf-I genetic variation and breast cancer: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2006; 15: 172-4.
9. Lukanova A, Lundin E, Toniolo P et al. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 2002; 101: 549-54.
10. Lukanova A, Lundin E, Micheli A et al. Risk of ovarian cancer in relation to prediagnostic levels of C-peptide, insulin-like growth factor binding proteins-1 and -2 (USA, Sweden, Italy). Cancer Causes Control 2003; 14: 285-92.
11. Ma J, Pollak MN, Giovannucci E et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999; 91: 620-5.
12. Feik E, Baierl A, Hieger B et al. Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk. Cancer Causes Control 2010; 21: 91-7.
13. Zha J, Lackner MR. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 2010; 16: 2512-7.
14. Shitara K, Ito S, Misawa K et al. Genetic Polymorphism of IGF1 Predicts Recurrence in Patients with Gastric Cancer Who Have Undergone Curative Gastrectomy. Ann Oncol 2011; doi: [Epub ahead of print].
15. Hamajima N, Matsuo K, Saito T et al. Gene-environment Interactions and Polymorphism Studies of Cancer Risk in the Hospital-based Epidemiologic Research Program at Aichi Cancer Center II (HERPACC-II). Asian Pac J Cancer Prev 2001; 2: 99-107.
16. Tajima K, Hirose K, Inoue M, Takezaki T, Hamajima N, Kuroishi T. A Model of Practical Cancer Prevention for Out-patients Visiting a Hospital: the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). Asian Pac J Cancer Prev 2000; 1: 35-47.
17. International HapMap Consortium. The International HapMap Project. Nature 2003; 426: 789-96.
18. Thorisson GA, Smith AV, Krishnan L, Stein LD. The International HapMap Project Web site. Genome Res 2005; 15: 1592-3.
19. Fukuda S, Shimoyama T, Umegaki N, Mikami T, Nakano H, Munakata A. Effect of Helicobacter pylori eradication in the treatment of Japanese patients with chronic idiopathic urticaria. J Gastroenterol 2004; 39: 827-30.
20. Sasazuki S, Inoue M, Iwasaki M et al. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1341-7.
21. Al-Zahrani A, Sandhu MS, Luben RN et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 2006; 15: 1-10.
22. Cheng I, Penney KL, Stram DO et al. Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2006; 15: 1993-7.
23. Patel AV, Cheng I, Canzian F et al. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE 2008; 3: e2578.
24. Johansson M, McKay JD, Wiklund F et al. Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels. J Clin Endocrinol Metab 2007; 92: 4820-6.